The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Abstract
Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchy‐mal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor‐alpha (ERα)‐positive (MCF‐7, T47D, BT474, and ZR‐75–1) and ERα‐negative (MDA‐MB‐231 and MDA‐MB‐468) human breast tumor cell lines. All ERα‐positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine‐705. Paracrine IL‐6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phos‐phorylation was lost when IL‐6 was depleted from MSC conditioned media or the IL‐6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ERα‐positive mammary tumor cell line MCF‐7 after paracrine and autocrine IL‐6 exposure, where MCF‐7 growth rates were enhanced by > 2‐fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL‐6 production.—Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., Hall, B. M. Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. FASEB J. 21, 3763–3770 (2007)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-6 is an MSC-secreted inflammatory cytokine displaying pro-survival, pro-growth and pro-angiogenic activities [11], which has been implicated in tumor progression of various cancers including breast cancer [113, 114].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [113]
In the citing paper
“The production of trophic factors from MSCs including VEGF, chemokine CCL5 and IL6 (activation STAT-3) has been connected with tumour growth and metastasis in Burkitt's lymphoma, breast cancer, colonic cancer and chronic myeloid leukaemia [69], [70], [71], [72], [73].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [70]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“Mesenchymal stem cells (MSC), also referred to as bone marrow stromal cells, are a common fibroblastic cell population within bone that regulates hematopoiesis, has a robust ability to self-renew, can differentiate into multiple mesenchymal cell lineages, and constitutively produces IL-6 ( 14 , 15).”
BackgroundCaplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“A growing body of evidence demonstrates that stromal cell fibroblasts are influential players in tumor progression and metastasis ( 9 ).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 3×
“Signal transducer and activator of transcription 3 (STAT3) is one of the primary intracellular targets activated after exposure to IL-6 (18), and STAT3 activation has been connected with enhanced tumor cell growth, survival, and immune evasion in breast cancer (22–24).”
BackgroundInfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“cancers including multiple myeloma (19), prostate”
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994 · cited 1×
“, C57BL/6, and FVB/N) as described (26) and maintained in RPMI 1640 complete media.”
BackgroundSelf-citationThe role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 950 · cited 1×
“Of interest, the bone marrow microenvironment in postmenopausal women maintains stable levels of IL-6 protein, regardless of systemic estradiol levels (33); therefore, it is possible that the bone marrow microenvironment may represent a more favorable tissue for IL-6-responsive ER -positive tumor cells (32, 34).”
Background
Research works printed but not linked: 1
- 10.1210/jc.81.2.513 · doi:10.1210/jc.81.2.513
Cited by
Items 101–200 of 222
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
Regulation of aromatase in cancer
Molehin, D., Rasha, F. A., Rahman, R. L., & Pruitt, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04099-0 · Cited by 40
Zhou, H., Chen, J., Hu, J., Luo, Y., Li, F., Xiao, L., & Mei-zuo, Z. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1616-4 · Cited by 43
“However, in other scenarios, this factor has been reported to promote tumor growth (Sasser et al. 2007; Yamaji et al. 2004).”
BackgroundRowan, B. G., Lacayo, E. A., Sheng, M., Anbalagan, M., Gimble, J. M., Jones, R. K., Joseph, W. J., Friedlander, P. L., & Chiu, E. S. (2015) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv090 · Cited by 36
The role of interleukin-6 in malignant mesothelioma.
Rahim, S. N. A., Ho, G., & Coward, J. I. G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.07.01 · Cited by 38
The Impact of Estrogen in the Tumor Microenvironment
Somasundaram, A., Rothenberger, N. J., & Stabile, L. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_2 · Cited by 40
Heparanase Accelerates Obesity-Associated Breast Cancer Progression
Hermano, E., Goldberg, R., Rubinstein, A. M., Sonnenblick, A., Maly, B., Nahmias, D., Li, J., Bakker, M. A. H., van der Vlag, J., Vlodavsky, I., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4058 · Cited by 38
Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells
Castellana, B., Aasen, T., Moreno‐Bueno, G., Dunn, S. E., & y Cajal, S. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5664 · Cited by 36
“MCF7 cells had low levels of pYB-1S102 (see Figure 1A) and respond to IL-6 via the IL-6 receptor components alpha (gp80) and gp130 [27].”
BackgroundSanmartin, M. C., Borzone, F. R., Giorello, M. B., Pacienza, N., Yannarelli, G., & Chasseing, N. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103416 · Cited by 36
Mesenchymal Stem Cells as Vectors for Lung Cancer Therapy
Kolluri, K. K., Laurent, G. J., & Janes, S. M. (2013) · Respiration · doi:10.1159/000351284 · Cited by 34
BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment
Andrieu, G. P., Shafran, J. S., Deeney, J. T., Bharadwaj, K. R., Rangarajan, A., & Denis, G. V. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0917-380rr · Cited by 35
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
“184,185 Chen et al. 186 discovered that MSCs upregulate the c-Myc-HK2 signaling pathway in gastric cancer cells by secreting HGF, thereby promoting gastric cancer cell proliferation and migration.”
BackgroundA comprehensive review on anticancer mechanism of bazedoxifene
Zafar, E., Maqbool, M. F., Iqbal, A., Maryam, A., Shakir, H. A., Irfan, M. I., Khan, M. N., Li, Y., & Ma, T. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2150 · Cited by 34
Avnet, S., Lemma, S., Cortini, M., Di Pompo, G., Perut, F., & Baldini, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00305 · Cited by 29
Co-Isolation of Cytokines and Exosomes: Implications for Immunomodulation Studies
Benjamin-Davalos, S., Koroleva, M., Allen, C. L., Ernstoff, M. S., & Shu, S. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638111 · Cited by 29
Sun, X., Gupta, K., Wu, B., Zhang, D., Yuan, B., Zhang, X., Chiang, H.-C., Zhang, C., Curiel, T. J., Bendeck, M. P., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000672 · Cited by 32
Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line
Wakabayashi, H., Hamaguchi, T., Nagao, N., Kato, S., Iino, T., Nakamura, T., & Sudo, A. (2018) · Breast Cancer · doi:10.1007/s12282-018-0853-9 · Cited by 29
EGF activates TTP expression by activation of ELK-1 and EGR-1 transcription factors
Florkowska, M., Tymoszuk, P., Balwierz, A., Skucha, A., Kochan, J. A., Wawro, M., Stalińska, K., & Kasza, A. (2012) · BMC Molecular Biology · doi:10.1186/1471-2199-13-8 · Cited by 29
“Among them IL-6, COX-2, c-FOS, urokinase, urokinase receptor, metalloproteinase-1 can be pointed out and notably, all of them are down-modulated at their mRNA level by tristetraprolin [6,38-40].”
BackgroundDiscovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation
Liu, H., Dowdle, J. A., Khurshid, S., Sullivan, N. J., Bertos, N., Rambani, K., Mair, M., Daniel, P., Wheeler, E., Tang, X., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.024 · Cited by 27
“All DsRed-positive human breast cancer cells were previously generated (Sasser et al., 2007a; Sasser et al., 2007b; Studebaker et al., 2008).”
BackgroundMethodSelf-citationAlanteet, A. A., Attia, H., Shaheen, S. Y., Al-Fayez, M., & Alshanawani, B. (2021) · Dose-Response · doi:10.1177/1559325821995651 · Cited by 33
Sasser, K., Casneuf, T., Axel, A. E., King, P., Alvarez, J. D., Werbeck, J. L., Verhulst, T., Verstraeten, K., & Hall, B. M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s92414 · Cited by 51
Self-citationHsp90 as a “Chaperone” of the Epigenome
Isaacs, J. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.09.003 · Cited by 32
RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
Gallo, M., Frezzetti, D., Roma, C., Chicchinelli, N., Barbieri, A., Arra, C., Scognamiglio, G., Botti, G., Luca, A. D., & Normanno, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24784 · Cited by 28
Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer
Hsu, E., Kulp, S. K., Huang, H.-L., Tu, H., Chao, M., Tseng, Y., Yang, M.-C., Salunke, S. B., Sullivan, N. J., Chen, W.-C., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw020 · Cited by 32
Self-citationThe Chemical Potential of Plasma Membrane Cholesterol: Implications for Cell Biology
Ayuyan, A. G., & Cohen, F. S. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.12.042 · Cited by 27
Gu, C., Wiest, M. J., Zhang, W., Halder, K., Zurawski, S., Zurawski, G., Joo, H., & Oh, S. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300029 · Cited by 28
Protective effects of eicosapentaenoic acid in adipocyte-breast cancer cell cross talk
Aljawadi, A., Rasha, F. A., Ramalingam, L., Alhaj, S., Moussa, H. M., Gollahon, L., Dharmawardhane, S., & Moustaïd‐Moussa, N. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108244 · Cited by 27
Effect of nanoemulsion particle size on the bioavailability and bioactivity of perilla oil in rats
Hu, M., Xie, F., Zhang, S., Qi, B., & Li, Y. (2020) · Journal of Food Science · doi:10.1111/1750-3841.15537 · Cited by 25
The role of miRNAs in cytokine signaling
McCoy, C. E. (2011) · Frontiers in bioscience · doi:10.2741/3845 · Cited by 28
Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-α
Zhao, X., Sun, X., Gao, F., Luo, J., & Sun, Z. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-22 · Cited by 24
“Sasser [6] found that the growth rate of MCF-7 estrogen-receptor-positive (ER+) breast carcinoma cells doubled in vitro and increased even more in vivo following treatment with recombinant human IL-6.”
BackgroundIdentification of novel small molecules that inhibit STAT3-dependent transcription and function
Kolosenko, I., Yu, Y., Busker, S., Dyczynski, M., Liu, J., Haraldsson, M., Palm‐Apergi, C., Helleday, T., Tamm, K. P., Page, B. D. G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178844 · Cited by 26
Zhang, F., Wang, Z., Yuan, J., Wei, X., Tian, R., & Niu, R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3529-6 · Cited by 23
The Molecular and Genetic Interactions between Obesity and Breast Cancer Risk
Ajabnoor, G. (2023) · Medicina · doi:10.3390/medicina59071338 · Cited by 28
“Secretion of these adipokines has been associated with tumor growth [32,72].”
BackgroundBone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?
Lipton, A., Costa, L., & Coleman, R. E. (2011) · Breast Disease · doi:10.3233/bd-2010-0327 · Cited by 22
“matory cytokines [22,23], some of which could also influence breast cancer cell growth and invasion [24].”
Alokail, M. S., Al‐Daghri, N. M., Mohammed, A. K., Vanhoutte, P. M., & Alenad, A. M. H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0038-0 · Cited by 31
Rhett, J. M., & Yeh, E. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041043 · Cited by 21
“One study showed that ERα-positive, but not ERα-negative, cell lines displayed enhanced growth in response to IL-6 in vitro, and in vivo, MCF-7 cells engineered to express ectopic human IL-6 displayed significantly greater tumor growth in athymic nude mice when compared to parental MCF-7 cells [86].”
BackgroundMing, W., Xie, H., Hu, Z., Chen, Y., Zhu, Y., Bai, Y., Liu, H., Sun, X. S., Liu, Y., & Gu, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00985 · Cited by 26
“Moreover, many studies suggested that cytokines play an important role in the regulation of both induction and protection in BC (46, 47).”
BackgroundYoon, N., Park, M. S., Peltier, G. C., & Lee, R. H. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.06.009 · Cited by 21
The dichotomy of placenta-derived cells in cancer growth
Silini, A. R., Cancelli, S., Signoroni, P. B., Cargnoni, A., Magatti, M., & Parolini, O. (2017) · Placenta · doi:10.1016/j.placenta.2017.05.011 · Cited by 20
Polyploid giant cancer cells, cytokines and cytomegalovirus in breast cancer progression
Ahmad, S. H., Baba, R. E., & Herbein, G. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02971-1 · Cited by 22
Oliphant, M. U. J., Akshinthala, D., & Muthuswamy, S. K. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01798-6 · Cited by 18
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_26 · Cited by 32
Notch signaling: mediator and therapeutic target of bone metastasis
Sethi, N. S., & Kang, Y. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.2 · Cited by 19
Kiyomi, A., Makita, M., Ozeki, T., Li, N., Satomura, A., Tanaka, S., Onda, K., Sugiyama, K., Iwase, T., & Hirano, T. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.06.004 · Cited by 17
“There is another report that suggests that IL-6 is a growth factor of three-dimensionally cultured ER(+) breast cancer cells in vitro and in vivo [17].”
BackgroundDittmer, A., Lange, T., Leyh, B., & Dittmer, J. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4918 · Cited by 24
Antoon, R., Wang, X., Saleh, A. H., Warrington, J., Hedley, D. W., & Keating, A. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.005 · Cited by 18
The Mesenchymal-Like Phenotype of the MDA-MB-231 Cell Line
Boon, K. (2011) · InTech eBooks · doi:10.5772/20666 · Cited by 16
Pohorelic, B. K. J., Singh, R., Parkin, S., Koro, K., Yang, A.-D., Egan, C., & Magliocco, A. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1753-2 · Cited by 21
Mesenchymal Stem/Stromal Cells in Cancer: from Initiation to Metastasis
Zheng, Z., Li, P., Shen, F., Shi, Y., & Shao, C. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.11.001 · Cited by 14
Hazlett, J., Niemi, V., Aiderus, A., Powell, K., Wise, L. M., Kemp, R. A., & Dunbier, A. K. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01472-1 · Cited by 18
“In addition, IL-6 has been shown to stimulate MCF-7 cells to proliferate in vitro and in vivo [39] while TNF is linked to increased invasiveness [40].”
BackgroundMaeda, M., Takami, T., Terai, S., & Sakaida, I. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07016.x · Cited by 14
D'Andrea, M. R., Cereda, V., Coppola, L., Giordano, G., Remo, A., & Santis, E. D. (2021) · Cancers · doi:10.3390/cancers13235917 · Cited by 18
Ghosh, S., Elankumaran, S., & Puri, I. K. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00739.x · Cited by 14
Natarajan, S., & Ranganathan, M. (2020) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2020.1797779 · Cited by 13
Elingaard-Larsen, L. O., Rolver, M. G., Sørensen, E. E., & Pedersen, S. F. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_23 · Cited by 15
Bimonte, V. M., Catanzaro, G., Pò, A., Trocchianesi, S., Besharat, Z. M., Spinello, Z., Curreli, M., Fabi, A., Bei, R., Milella, M. S., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03594-2 · Cited by 12
Chen, C., Wang, Z., Liao, Z., Zhang, Y., Lei, W., & Shui, X. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.13134 · Cited by 12
Dai, B., Clark, A. M., & Wells, A. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137133 · Cited by 12
Variability of the paracrine‐induced osteoclastogenesis by human breast cancer cell lines
Costa‐Rodrigues, J., Moniz, K. A., Teixeira, M. R., & Fernandes, M. H. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23439 · Cited by 13
“…the aim of this work is to compare the paracrine-induced osteoclastogenesis mediated by four human breast cancer cell lines, the estrogen-receptor positive T47D and MCF-7 cell lines [Sasser et al., 2007] and the estrogennegative SK-BR-3 and Hs-578T cell lines [Oh et al., 1993; Liu et al., 2009].”
BackgroundGallo, M., Carotenuto, M., Frezzetti, D., Camerlingo, R., Roma, C., Bergantino, F., Normanno, N., & Luca, A. D. (2022) · Cancers · doi:10.3390/cancers14071851 · Cited by 16
Ding, X., Zhang, J., Liu, D., Xu, W., Lu, D., Zhang, L., & Su, B. (2018) · Journal of Cancer · doi:10.7150/jca.22656 · Cited by 12
“IL-6 is reported to be involved in tumor progression of breast cancer[16] in molecular experiments[17] and clinical outcomes[18], and also in prostate cancer[19, 20].”
BackgroundEstrogen Prevents Senescence through Induction of WRN, Werner Syndrome Protein
Lee, S., Lee, S.-H., Ha, N., & Park, B.-J. (2010) · Hormone Research in Paediatrics · doi:10.1159/000313366 · Cited by 13
Motoyama, S., Nakatsu, T., Miura, M., Hinai, Y., Minamiya, Y., & Ogawa, J. (2012) · Digestive Surgery · doi:10.1159/000336952 · Cited by 11
Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
Papadimitropoulou, A., Vellón, L., Atlas, E., Steen, T. V., Cuyàs, E., Verdura, S., Espinoza, I. C., Menéndez, J. A., & Lupu, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207737 · Cited by 11
Breast cancer: Interaction between oxidant-antioxidant dynamics and inflammation in Indian females
Goswami, B., Rajappa, M., Gupta, N., Mahto, M., Hadke, N. S., & Mishra, T. K. (2009) · Cancer Biomarkers · doi:10.3233/cbm-2009-0122 · Cited by 11
Stem Cell Biology in Health and Disease
Dittmar, T., & Zänker, K. S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3040-5 · Cited by 12
The ASC: Critical Participants in Paracrine-Mediated Tissue Health and Function
Zuk, P. A. (2013) · InTech eBooks · doi:10.5772/55545 · Cited by 12
Al‐Saeedi, F. J. (2023) · Molecules · doi:10.3390/molecules28052101 · Cited by 10
Bakheet, M. M., Ali, H. S., & Talab, T. J. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156632 · Cited by 16
Cell-cell interactions mediating primary and metastatic breast cancer dormancy
Lenart, N. A., & Rao, S. S. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10223-5 · Cited by 11
Sergi, D., Melloni, M., Passaro, A., & Neri, L. M. (2024) · Nutrients · doi:10.3390/nu16193243 · Cited by 10
Itou, J., Tanaka, S., Sato, F., Akiyama, R., Kawakami, Y., & Toi, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.004 · Cited by 9
Yang, C. M., Chiba, T., & Groner, B. (2012) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2012-0003 · Cited by 9
Mosly, D., MacLeod, K. G., Moir, N., Turnbull, A., Sims, A. H., & Langdon, S. P. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110563 · Cited by 9
IL-6-transfected tumor cells modulate the status of CD8+ and CD4+ T cells to control tumor growth
Hsieh, C.-L., Liu, S., Shen, C., Chen, M., Hsu, S.-C., Tsai, J.-P., Li, Y.-S., Yang, C., Chong, P. C.-S., & Chen, H. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.07.003 · Cited by 8
Enayatjazi, M., Esfarjani, F., Reisi, J., & Moshtaghian, S. J. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_315_20 · Cited by 8
“[6] IL‐6 is the strong growth factor and promotes epithelial‐mesenchymal phenotype (EMT) in breast cancer cells, implying that IL‐6 is found in the tumor micro environment.[7] IL‐6 increases the expression of the vascular endothelial growth factor (VEGF), thereby contributing to the increased intravascular angiogenesi…”
BackgroundÇelik, P. A., Eken, A., Derya-Andeden, M., Eci̇roglu, H., Üzen, R., & Dönmez‐Altuntaş, H. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106121 · Cited by 7
Dastagir, N., Liebsch, C., Kutz, J. N., Wronski, S., Pich, A., Obed, D., Vogt, P. M., Bucan, V., & Strauß, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316257 · Cited by 7
“Therefore, high levels of IL-6 correlate with a poor prognosis for breast cancer patients [46].”
Sistanipour, E., Meshkini, A., & Oveisi, H. (2023) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2023.132947 · Cited by 7
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A. H., Hall, B. M., Andreeff, M., & Marini, F. C. (2013) · PLoS ONE · doi:10.1371/annotation/4ab4c130-16cb-41f0-9507-b00ce070fbc6 · Cited by 7
Self-citationLotfy, E. M., Bokhtia, R. M., Fattah, H. A. A., & Seliem, I. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118165 · Cited by 6
Moaiedi, M. Z., AHMADPOOR, F., Rashidi, M., AHMADZADEH, A., Salmasi, A., & Mohammadzadeh, G. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2008-292 · Cited by 7
“Previous studies indicated that a high serum level of IL-6 and its soluble receptor has an independent prognostic value, and is associated with the extent and tumor grade of breast cancer [13,27].”
BackgroundEpithelial Stem Cells: Making, Shaping and Breaking the Niche
Ferraces-Riegas, P., Galbraith, A. C., & Doupé, D. P. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_686 · Cited by 6
Universal and Specific Functions of STAT3 in Solid Tumours
Avalle, L., Regis, G., & Poli, V. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0891-8_17 · Cited by 7
“These cells were shown to enhance tumour aggressivity and growth rates in ER-alphanegative breast cancer cell lines via IL-6 secretion and STAT3 activation (Sasser et al. 2007).”
BackgroundLes cellules souches mésenchymateuses: Armes ou dangers pour le traitement des cancers ?
Lazennec, G. (2011) · médecine/sciences · doi:10.1051/medsci/2011273285 · Cited by 8
Yao, W., Hua, D.-M., Zhang, Y., Zhao, Y., Feng, Y., Zhang, Z., Ni, Z., Guo, H., Guan, Y., & Wang, Y. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04860-8 · Cited by 6
Involvement of Mesenchymal Stem Cells in Breast Cancer Progression
Dittmer, J., Oerlecke, I., & Leyh, B. (2011) · InTech eBooks · doi:10.5772/21325 · Cited by 8
“Growth-stimulating effects of MSCs were also found on other ER-positive breast cancer cell lines, including T47D, BT474 and ZR-75-1 (Sasser et al., 2007a) and may be dependent on similar mechanisms as those on MCF-7 cells.”
BackgroundInfluentialJang, S.-H., Paek, S. H., Kim, J., Seong, J. K., & Lim, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119474 · Cited by 4
Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance
Husain, A., Khan, H., Fatima, J. E., Siddiqui, S. A., Singh, A. D., Husain, A., Pandey, S., Kant, R., Khanam, A., Pandey, P., et al. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010343901250204054241 · Cited by 4
Abd-Elaziz, C. K., Moneim, N. A. A. E., Fek, S. E. E., & Arafat, A. M. (2019) · Advances in Breast Cancer Research · doi:10.4236/abcr.2019.83009 · Cited by 4
Sarf, E. A., Dyachenko, E. I., & Bel’skaya, L. V. (2024) · Biomedicines · doi:10.3390/biomedicines12061329 · Cited by 4
“In this case, ER+ cells secrete lower levels of IL-6 than ER-cells since estrogen inhibits the expression of IL-6, impairing the transactivation of NF-κ B [56–59].”
BackgroundTobin, G., Kalupahana, R. S., & Kulk, M. (2013) · InTech eBooks · doi:10.5772/55794 · Cited by 4
Mesenchymal Stem Cells in Tumor Stroma
Sullivan, N. J., & Hall, B. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-933-8_3 · Cited by 5
Self-citationAbd-Elfadel, A. A., Ewees, M. G., Aboud, H. M., Rouby, W. M. A. E., Farghali, A. A., & Zanaty, M. I. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107395 · Cited by 4
Nicolini, A., Rossi, G., & Ferrari, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1225175 · Cited by 6
Targeting Tumor Stroma: Current Challenges and Future Directions
Wang, S., Hu, H., Zeng, W., Qin, L., Chen, X., Liao, Z., Liu, F., & Zhang, Z. (2026) · MedComm · doi:10.1002/mco2.70763 · Cited by 3
Angiogenesis and Bone Metastasis: Implications for Diagnosis, Prevention and Treatment
Tsoutsou, P. P., & Koukourakis, M. I. (2009) · Cancer metastasis · doi:10.1007/978-1-4020-9819-2_3 · Cited by 2
Interleukin-6 in the Breast Tumor Microenvironment
Nicholas, J. (2011) · InTech eBooks · doi:10.5772/21947 · Cited by 2
“…and common sites of breast cancer metastasis such as bone and lung enhance the growth of breast cancer cells in an IL-6-dependent manner, and IL-6 is the major fibroblast-derived soluble factor that induced STAT3 activation in breast cancer cells (Sasser et al., 2007; Studebaker et al., 2008).”
BackgroundInfluentialProperties of Mesenchymal Stem Cells to Consider for Cancer Cell Therapy
Stagg, J., & Pommey, S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3040-5_5 · Cited by 3
Arfian, N., Budiharjo, S., Kencana, S. M. S., Susanto, E. H., Suhardi, D. Y., Pramudita, B. D., Sari, D. C. R., & Romi, M. M. (2018) · International Conference on Bioinformatics, Biotechnology and Biomedical Engineering (BioMIC) · doi:10.1109/biomic.2018.8610552 · Cited by 2
Metadata
- Authors
- Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M.
- Affiliations
- The Ohio State University (US)
- Center for Childhood Cancer Children's Research Institute Columbus Ohio USA
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-06-22
- Volume
- 21
- Issue
- 13
- Pages
- 3763-3770
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1973576115
- Cited by
- 222
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 14 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Elsa U. Pardee Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- interleukin-6, estrogen receptor alpha, breast cancer, mesenchymal stem cells, STAT3 phosphorylation, bone metastasis, paracrine signaling, autocrine signaling, tumor growth, MCF-7 cells, IL-6 receptor
- MeSH terms
- Breast Neoplasms, Humans, Interleukin-6, Cell Line, Tumor, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.